# ORIGINAL ARTICLE

# Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors—results from a Dutch population-based study

Simone Oerlemans • Olga Husson • Floortje Mols • Philip Poortmans • Henk Roerdink • Laurien A. Daniels • Carien L. Creutzberg • Lonneke V. van de Poll-Franse

Received: 17 January 2012 / Accepted: 7 May 2012 / Published online: 26 May 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract To improve posttreatment care for (long-term) lymphoma survivors in the Netherlands, survivorship clinics are being developed. As information provision is an important aspect of survivorship care, our aim was to evaluate the current perceived level of and satisfaction with information received by non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) survivors, and to identify associations with sociodemographic and clinical characteristics. The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with NHL, HL and MM from 1999 to 2009. In total, 1,448 survivors received a questionnaire, and 1,135 of them responded (78.4 %). The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with

S. Oerlemans (⊠) • O. Husson • F. Mols • L. V. van de Poll-Franse Research Department, Comprehensive Cancer Centre South, PO Box 231, 5600 AE Eindhoven, the Netherlands e-mail: s.oerlemans@ikz.nl

S. Oerlemans · O. Husson · F. Mols · L. V. van de Poll-Franse Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, the Netherlands

P. Poortmans Department of Radiation therapy, Institute Verbeeten, Tilburg, the Netherlands

H. Roerdink Department of Oncology and Hematology, Twee Steden Hospital, Tilburg, the Netherlands

L. A. Daniels · C. L. Creutzberg Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands information. Two thirds of survivors were satisfied with the amount of received information, with HL survivors being most satisfied (74 %). At least 25 % of survivors wanted more information. Young age, having had chemotherapy, having been diagnosed more recently, using internet for information and having no comorbidities were the most important factors associated with higher perceived levels of information provision. Although information provision and satisfaction with information seems relatively good in lymphoma and MM survivors, one third expressed unmet needs. Furthermore, variations between subgroups were observed. Good information provision is known to be associated with better quality of life. Survivorship care plans could be a way to achieve this.

**Keywords** Information provision · Patient satisfaction · Lymphoma · Multiple myeloma · Cancer survivors · Population-based

#### Introduction

On January 1, 2009 there were approximately 21,000 non-Hodgkin lymphoma (NHL), 5,300 Hodgkin lymphoma (HL), and 3,300 multiple myeloma (MM) survivors in the Netherlands [1]. These numbers are expected to increase to approximately 32,000 NHL, 6,300 HL and 4,300 MM survivors by 2020 [1]. This substantial rise will result in an increasing health care burden in haematology, especially indolent lymphomas and MM, which both are characterised by a prolonged clinical course with repeated relapses and slow but ongoing progression [2].

To improve care for this growing group of cancer survivors, a nationwide initiative of haematologists, radiation oncologists, epidemiologists and internists has founded a Working Group named "BETTER" ("BETER" in Dutch), which is currently developing protocols for standardized long-term care for HL and NHL survivors and establishing survivorship clinics. The goals of these clinics are to minimize the occurrence and influence of late effects and to improve survivors' quality of life (QoL) by: informing survivors about long-term risks, advice preventive measures, suggest screening and improve aftercare by providing rehabilitation programmes [3].

Patient information is an essential component of cancer care and rehabilitation [4]. Patients, who are well informed about their cancer, treatment, and aftercare, are more likely to complete their therapy and are less anxious thereafter [5, 6]. Providing adequate information to cancer patients can reduce the psychological burden and improve patients' QoL and their satisfaction with care [7, 8]. This is important since lymphoma and MM survivors report lower QoL compared to normative populations even years after diagnosis [9, 10].

Up to now, no studies have investigated the perceived level of and satisfaction with information provision in NHL, HL and MM survivors. If factors associated with information satisfaction are known, health care providers can better give adequate information to those who need it, which can contribute to an improved quality of care and QoL. The aim of the present study was therefore to measure the perceived level of, and satisfaction with information received by survivors of indolent NHL (I-NHL), aggressive NHL (A-NHL), HL and MM, and to identify associations with sociodemographic and clinical characteristics for each tumour type.

## Methods

## Setting and population

This study is part of a dynamic longitudinal populationbased survey among lymphoma and MM survivors registered within the Eindhoven Cancer Registry (ECR) of the Comprehensive Cancer Centre South and is embedded in Population-Based HAematological Registry for Observational Studies. The ECR records data on all patients who are newly diagnosed with cancer in the southern part of the Netherlands, an area with 2.3 million inhabitants, 18 hospital locations and 2 large radiotherapy institutes. The ECR was used to select all patients who were diagnosed with NHL, HL and MM between January 1, 1999 and January 1, 2009. We included all subtypes of indolent (including chronic lymphocytic leukaemia-like) and aggressive B cell NHL, HL and MM as defined by the International Classification of Diseases for Oncology-3 codes [11]. Deceased patients were excluded by linking the ECR database with the Central Bureau for Genealogy. Ethical approval for the study was obtained from a regional, certified Medical Ethics Committee.

### Data collection

Data collection took place in 2009 and was done within PROFILES (Patient Reported Outcomes Following Initial treatment and Long-term Evaluation of Survivorship). PRO-FILES is a registry for the study of the physical and psychosocial impact of cancer and its treatment from a dynamic, growing population-based cohort of both shortand long-term cancer survivors. PROFILES contains a large web-based component and is linked directly to clinical data from ECR. Details of the data collection method have been previously described [12]. Data from the PROFILES registry will become available for noncommercial scientific research, subject to study question, privacy and confidentiality restrictions, and registration (www.profilesregistry.nl).

In May 2009, patients between 1 and 10 years after diagnosis were included in the study and received the first questionnaire. In November 2009, patients diagnosed between May and November 2009 were invited to participate.

### Study measures

The Dutch version of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-INFO25 questionnaire was used to evaluate the perceived level of and satisfaction with information among NHL, HL and MM patients [13]. This 25-item questionnaire incorporates four information provision subscales: perceived receipt of information about the disease, medical tests, treatment and other care services. Additionally, it contains several single items on receiving written information or information on CD or tape/video and items on the satisfaction with and helpfulness of the received information. Answer categories range from one (not at all) to four (very much), except for four items which have a two-point scale. Furthermore, an open question is asked on what topics survivors would like to receive more information on. After linear transformation, all scales and items range in scores from 0 to 100, with higher scores indicating better perceived information provision. The questionnaire has been internationally validated, and internal consistency for all scales is good (>0.70), as is test-retest reliability (interclass correlations >0.70) [14]. Our data revealed Cronbach's alphas of 0.75 (disease), 0.88 (medical test), 0.88 (treatment) and 0.82 (other services) for the four subscales, respectively. In addition to the EORTC QLQ-INFO25,

we asked patients two single questions about the use of internet for seeking additional information, which could be answered with either yes or no.

Comorbidity at time of survey was categorized according to the adapted Self-administered Comorbidity Questionnaire [15]. Questions on survivors' marital status and educational level were also added to the questionnaire. Clinical information was available from the ECR that routinely collects data on tumour characteristics, including date of diagnosis, histology, Ann Arbor stage (where appropriate) [16], primary treatment and patients' background characteristics, including gender and date of birth.

## Statistical analysis

All statistical analyses were performed using SPSS version 17.0 (Statistical Package for Social Sciences, Chicago, IL, USA) and p values of <.05 were considered statistically significant. For the EORTC QLQ-INFO25, we used a score of  $\geq$ 10 points difference on subscales to define a clinical important difference [17].

Differences in sociodemographic and clinical characteristics between respondents, non-respondents and patients with unverifiable addresses and between tumour types were compared with a chi-square, t test or its nonparametric equivalent where appropriate.

Multi-item scales of the EORTC QLQ-INFO25 were included in the analyses if at least half of the items from the scale were answered, according to the EORTC QoL guidelines [13, 14, 18]. ANOVA and chi-square were performed to investigate mean differences between tumour type (independent variables) and the EORTC QLQ-INFO25 scales (dependent variables).

Multivariate regression analyses were performed to investigate the independent association of sociodemographic and clinical characteristics with the subscales of the EORTC QLQ-INFO25. All sociodemographic and clinical variables were included; this was determined a priori. Stage was only included in the analyses for A-NHL and HL since it was not available for I-NHL and MM (Table 1).

Logistic regression analyses were performed with received information satisfaction as outcome measure, one for the total group and four for the tumour types. Therefore, patients were categorized into two groups: (a) patients who were unsatisfied or only a little satisfied, classified as unsatisfied and (b) patients who were quite satisfied or very satisfied, classified as satisfied. Again, all sociodemographic and clinical variables were included. Stage was only included in the analyses for A-NHL and HL since stage was not available in I-NHL and MM.

#### Results

Patient and tumour characteristics

Of the 1,448 lymphoma and MM survivors who were sent a questionnaire, 1,135 (78 %) completed it. Non-respondents were more recently diagnosed and less often diagnosed with stage I disease. Furthermore, they were less often treated with chemotherapy compared to respondents. Patients with unverifiable addresses were younger, diagnosed less recent, less often treated with chemotherapy and more often had active surveillance as primary treatment compared to respondents. There were no differences in response according to tumour type or gender (Table 1).

Participating HL survivors were significantly younger, more often had a job and reported fewer comorbid conditions than I-NHL, A-NHL and MM survivors. MM survivors were most recently diagnosed compared to the other three tumour groups (Table 2).

Satisfaction with and amount of information

Satisfied cancer survivors (n=724; 67 %) perceived to have received more information (disease, medical tests, treatment and other services) and found the information more useful than dissatisfied patients (n=411; 33 %), with mean differences ranging between 46 and 74 points (all p<0.01).

In total, 29 % of survivors would have liked to receive more information (29 % I-NHL, 25 % A-NHL, 30 % HL and 29 % MM). Most frequently mentioned topics to receive more information about were cause and course of disease (45 % I-NHL, 59 % A-NHL, 24 % HL and 54 % MM), late effects of treatment (46 % I-NHL, 37 % A-NHL, 50 % HL and 30 % MM) and psychosocial aftercare (10 % I-NHL, 23 % A-NHL, 26 % HL and 30 % MM).

Associations with perceived level of and satisfaction with information

Mean scores on perceived level of and satisfaction with information on all scales were the highest for HL survivors and the lowest for I-NHL survivors (Table 3). Furthermore, HL survivors found the information more useful compared to all other tumour groups.

Multivariate linear regression analyses including all patients in one model showed that receiving more disease-related information was associated with having no comorbid conditions, using internet for information and hospital ( $\beta$ =.11; p<.01; Table 4). More information on medical tests was associated with less comorbidity, high education and use of internet. Furthermore, receiving more information about treatment and other services was associated with younger age, having had chemotherapy, less comorbidity and hospital ( $\beta$ 

Fable 1	I Sociodemographic and	d clinical characteristics o	f questionnaire respond	lents, non-respondents and	l patients with unverifiable addresses
---------	------------------------	------------------------------	-------------------------	----------------------------	--

	Respondents N=1,135	Non-respondents $N=313$	Patients with unverifiable addresses $N=271$	p value
Tumour type				0.06
I-NHL	443 (39 %)	140 (45 %)	110 (41 %)	
A-NHL	375 (33 %)	80 (26 %)	82 (30 %)	
HL	164 (14 %)	37 (12 %)	44 (16 %)	
MM	153 (14 %)	56 (23 %)	35 (13 %)	
Age (at time of survey) (mean±SD)	61.6 (14)	60.5 (16)	57.2 (16)	< 0.01
<55	312 (28 %)	104 (33 %)	113 (42 %)	
55-69	452 (40 %)	99 (32 %)	79 (29 %)	
≥70	369 (33 %)	110 (35 %)	79 (29 %)	
Years since diagnosis (mean±SD)	3.7 (2.7)	3.2 (3.0)	3.9 (2.9)	< 0.01
0–1	313 (28 %)	130 (42 %)	71 (26 %)	
2–4	422 (37 %)	92 (29 %)	102 (38 %)	
5–7	264 (23 %)	46 (15 %)	56 (21 %)	
8–10	136 (12 %)	45 (14 %)	42 (16 %)	
Gender				0.38
Male	677 (60 %)	184 (59 %)	147 (55 %)	
Female	457 (40 %)	127 (41 %)	120 (45 %)	
Stage at diagnosis				< 0.01
Ι	248 (22 %)	52 (17 %)	65 (24 %)	
II	220 (19 %)	57 (18 %)	39 (14 %)	
III	183 (16 %)	40 (13 %)	42 (16 %)	
IV	218 (19 %)	50 (16 %)	58 (21 %)	
Unknown	266 (23 %)	114 (36 %)	67 (25 %)	
Primary treatment				
Radiotherapy	88 (7.8 %)	17 (5.4 %)	20 (7.4 %)	0.09
Chemotherapy	515 (45 %)	118 (38 %)	106 (39 %)	0.02
Chemotherapy+radiotherapy	239 (21 %)	56 (18 %)	52 (19 %)	0.11
Active surveillance <sup>a</sup>	233 (21 %)	89 (23 %)	71 (26 %)	< 0.01
Stem cell transplantation	58 (5.1 %)	16 (5.1 %)	8 (3.0 %)	0.07

*I-NHL* indolent non-Hodgkin lymphoma, *A-NHL* aggressive non-Hodgkin lymphoma, *HL* Hodgkin lymphoma, *MM* multiple myeloma <sup>a</sup> Patients are under active surveillance and receive no therapy

between .08 and .10; p<.05). Being diagnosed with I-NHL and being under active surveillance were associated with a lower perceived level of receiving information about treatment. Satisfaction with information was independently associated with having had chemotherapy and negatively associated with comorbidity.

Additional multivariate analyses within the different tumour types showed similar findings (data not shown in table). Younger age ( $\beta$  between -.13 and -.46; p<.05) and a more recent diagnosis ( $\beta$  between -.10 and -.20; p<.05) were frequently positively associated with perceived information provision, whereas comorbidity ( $\beta$  between -.13 and -.23; p<.05) was frequently negatively associated with perceived information provision.

I-NHL survivors with a low or medium educational level reported lower levels of treatment information ( $\beta$ =-.15;

p<.05) compared to those who were highly educated. A-NHL survivors with stage II or III disease ( $\beta$ =.22; p<.01) or those who received chemotherapy ( $\beta$ =.17; p<.01) reported higher perceived levels of information compared to those who did not. HL survivors with a low educational level ( $\beta$ =.23; p<.05) and those using internet ( $\beta$ =-.18; p<.05) reported higher levels of perceived information. Lastly, MM survivors under active surveillance reported lower perceived levels of information about treatment ( $\beta$ =-.45; p<.05) compared to patients who were actively treated.

## Discussion

In the present study among 1,135 NHL, HL and MM survivors, two thirds of survivors were satisfied with the

## Table 2 Sociodemographic and clinical characteristics of cancer survivors, stratified by tumour type

	I-NHL N=443	A-NHL <i>N</i> =375	HL N=164	MM <i>N</i> =153	p value
Age (at time of survey) (mean $\pm$ SD)	64.1 (11)	63 3 (14)	46.6 (15)	66.1 (10)	<0.01
<55	90 (20 %)	90 (24 %)	112 (69 %)	20 (13 %)	-0.01
55 60	90 (20 70) 100 (45 %)	136(36%)	38(23.0%)	20 (13 %)	
>70	154 (35 %)	148 (40 %)	13 (8 0 %)	54 (35 %)	
Years since diagnosis (mean+SD)	40(27)	35(26)	44(29)	24(23)	< 0.01
	100 (23 %)	108 (29 %)	36 (22 %)	69 (45 %)	-0.01
2_4	169 (38 %)	108 (29 %)	50 (22 %)	59 (39 %)	
5_7	113 (26 %)	85 (23 %)	49 (30 %)	17 (11 %)	
8_10	61 (14 %)	38 (10 %)	29 (18 %)	8 (5 2 %)	
Gender	01 (14 70)	56 (10 70)	27 (10 70)	0 (3.2 70)	0.10
Male	266 (60 %)	239 (64 %)	89 (54 %)	83 (55 %)	0.10
Female	177 (40 %)	136 (36 %)	75 (46 %)	69 (45 %)	
Stage at diagnosis	177 (40 70)	150 (50 70)	/5 (40 /0)	07 (45 70)	< 0.01
I	NΔ	118 (32 %)	30 (18 %)	NΔ	\$0.01
П	NA	90 (24 %)	83 (51 %)	NA	
III	NA	68 (18 %)	33 (20 %)	NA	
IV	NA	93 (25 %)	17 (10 %)	NA	
Unknown	NA	6 (1.6 %)	1 (0.6 %)	NA	
Primary treatment	1471	0 (1.0 70)	1 (0.0 70)	14/1	
Radiotherapy (only)	64 (14 %)	12 (3.2 %)	4 (2.4 %)	8 (5 2 %)	< 0.01
Chemotherapy (only)	157 (35 %)	235 (63 %)	65 (40 %)	58 (38 %)	< 0.01
Chemotherapy+radjotherapy	14 (3.2 %)	98 (26 %)	94 (57 %)	33 (22 %)	< 0.01
Active surveillance <sup>a</sup>	187 (42 %)	25 (6.7 %)	1 (0.6 %)	20 (13 %)	< 0.01
Stem cell transplantation	8 (1.8 %)	22 (5.9 %)	0 (0 %)	28 (18 %)	< 0.01
Comorbidity	· · · ·		( )	~ /	< 0.01
None	108 (26 %)	103 (30 %)	75 (48 %)	26 (19 %)	
1	122 (30 %)	118 (34 %)	46 (30 %)	43 (31 %)	
2	90 (22 %)	65 (19 %)	14 (9.0 %)	35 (26 %)	
3 or more	90 (22 %)	60 (17 %)	20 (13 %)	33 (24 %)	
Marital status					0.41
Partner	353 (81 %)	287 (79 %)	122 (75 %)	116 (77 %)	
No partner	84 (19 %)	77 (21 %)	41 (25 %)	35 (23 %)	
Education level					0.11
Low	69 (16 %)	62 (17 %)	16 (9.8 %)	30 (20 %)	
Medium	264 (61 %)	219 (61 %)	99 (61 %)	95 (63 %)	
High	101 (23 %)	80 (22 %)	48 (29 %)	27 (18 %)	
Current occupation					< 0.01
Employed	166 (46 %)	128 (45 %)	112 (84 %)	39 (34 %)	
Not working/retired	198 (54 %)	155 (55 %)	21 (16 %)	76 (66 %)	
Follow-up care					< 0.01
No	42 (10 %)	32 (10 %)	12 (8 %)	30 (24 %)	
2–4 times a year	324 (80 %)	245 (74 %)	81 (52 %)	95 (75 %)	
Once a year	35 (9 %)	52 (16 %)	62 (40 %)	1 (1 %)	
Once every 2 years	3 (1 %)	2 (1 %)	1 (1 %)	0 (0 %)	

*I-NHL* indolent non-Hodgkin lymphoma, *A-NHL* aggressive non-Hodgkin lymphoma, *HL* Hodgkin lymphoma, *MM* multiple myeloma, *NA* not available; education levels included *low* no/primary school, *medium* lower general secondary education/vocational training, or *high* pre-university education/high vocational training/university.

<sup>a</sup> Patients are under active surveillance and receive no therapy

Fable 3	Mean EORTC	QLQ-INFO25	subscale scores	(±SD)	according to tumour type	
---------	------------	------------	-----------------	-------	--------------------------	--

	I-NHL N=443 Mean (SD)	A-NHL N=375 Mean (SD)	HL N=164 Mean (SD)	MM N=153 Mean (SD)	p value	
EORTE QEQ-INTO25	Meall (SD)	Wiedli (SD)	Wiedli (SD)	Wiedli (SD)		
Information about disease	50 (22)	53 (20)	56 (16)	51 (22)	< 0.05 <sup>a</sup>	
Information about medical tests	63 (22)	64 (23)	68 (21)	65 (23)	0.15	
Information about treatment	41 (24)	50 (21)	57 (19)	47 (24)	<0.01 <sup>b</sup>	
Information about other services	16 (21)	25 (24)	27 (22)	22 (21)	<0.01 <sup>c</sup>	
Satisfaction with information	60 (28)	61 (26)	66 (25)	61 (28)	0.15	
Usefulness of information	62 (25) % Yes	66 (24) % Yes	73 (21) % Yes	62 (25) % Yes	< 0.01 <sup>d</sup>	
Want more information	29 %	25 %	30 %	29 %	0.48	
Want less information	3 %	3 %	2 %	1 %	0.74	

EORTC-QLQ INFO25 scales 0-100: a higher score reflects better perceived information received

I-NHL indolent non-Hodgkin lymphoma, A-NHL aggressive non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma

amount of received information about their haematological malignancy, respectively 65 % of I-NHL, 67 % of A-NHL, 74 % of HL and 68 % of MM survivors. However, variations were observed, and at least a quarter of survivors wanted more information, with large differences between hospitals (range, 24–40 %).

Younger age, having had chemotherapy, using internet for information and having no comorbid conditions appeared to be the most important factors associated with higher perceived levels of information provision. Analyses per tumour type showed similar findings. Worth mentioning is that in the analyses per tumour, I-NHL, A-NHL and MM survivors who had been diagnosed more recently had higher perceived levels of information provision, which possibly indicates that information provision has improved with time. However, it is also possible that recall bias influenced these findings, for those diagnosed more recently, the information received is still fresh in their memory and by the more frequent contacts with their physician in the phase more closely to diagnosis.

Our findings that the perceived level of information provision is associated with age, education, time since diagnosis and disease stage are in line with other studies [19–24]. Studies have shown that older and lower educated patients tend to ask fewer questions during their visit with their physician, and might therefore receive less information [25, 26]. Furthermore, older patients have been found to take a more passive role in interaction with their physician and have a greater reliance that their physician will provide all information [24]. In addition, higher educated patients are more likely to seek information from other sources such as the internet and consequently obtain more information [24].

The results of our study, with 67 % of survivors being satisfied with the amount of information received, were different compared to a study among mostly early-stage melanoma survivors in which only 39 % of survivors indicated to be satisfied [22]. These differences might be explained by the more chronic level and intense treatment of lymphoma and MM compared to early-stage melanoma. In addition, lymphoma and MM survivors will have more visits with the physician and therefore a possible improved information provision. Patients' satisfaction is also influenced by patients' expectations of the course of their disease [27]. Patients' expectations can vary widely, depending of the type of tumour [27]. HL survivors may be more satisfied with and score better on perceived information since they have a better prognosis compared to NHL and MM survivors.

Survivors who were satisfied with the received information scored significantly and clinically relevant higher on all information provision subscales and on the usefulness of information scale compared to the unsatisfied survivors. To improve information provision in the group of unsatisfied survivors, physicians could screen their patients by asking if they are satisfied with the amount of information received, and when unsatisfied, physicians can ask what the patients' information needs are.

To provide the needed (written) information to patients, physicians should think of the educational level of the information provision. Patients with a lower educational level and patients with a low level of literacy will need extra help to understand the information. In the USA, more attention is being paid to health literacy [20, 21, 28], i.e. "the degree to which individuals have the capacity to obtain, process and understand basic health information and services needed to make appropriate health decisions" [29], than in the Netherlands. Since our and other studies have observed that lower educated survivors report worse scores, more attention should be paid to providing information on a basic comprehensive level [19, 22, 23].

Innour type           I-NHL $-0.07$ $-0.12^{**}$ $-0.09$ $0.89 (0.52 - 1.52)$ A.NHL $-0.05$ $-0.07$ $-0.04$ $0.03$ $0.783 (0.48 - 1.28)$ HL         Ref         Ref         Ref         Ref         Ref           MM $-0.05$ $0.02$ $-0.03$ $0.00$ $0.81 (0.43 - 1.56)$ Age $-0.05$ $0.01$ $-0.12^{**}$ $-0.11^{**}$ $1.00 (0.99 - 1.01)$ Years since diagnosis $-0.01$ $0.01$ $0.02$ $-0.05$ $0.97 (0.92 - 1.03)$ Gender		Disease (Beta)	Medical tests (Beta)	Treatment (Beta)	Other (Beta)	Satisfaction with received information (odds±95 % CI)																																																																																																																																					
I-NHL-0.07-0.07-0.02**-0.090.89 (0.52-1.52)A-NHL-0.05-0.07-0.040.030.783 (0.48-1.28)HLRefRefRefRefRefMM-0.050.02-0.030.000.81 (0.43-1.56)Age-0.050.01-0.12**-0.11**1.00 (0.99-1.01)Year since diagnosis-0.050.010.02-0.050.97 (0.92-1.03)GenderMaleRefRefRefRefRefRefFemale0.010.02-0.01-0.010.97 (0.58-1.03)ChemotherayNoRefRefRefRefRefRefYes0.03-0.010.14*1.81 (1.04-3.13)*RadiotherayNoRefRefRefRefYes0.03-0.010.14*RefRef-Yes0.03-0.06-0.061.91 (0.06-1.45)YesRefRefRefRefYes0.04-0.060.061.51 (0.73-3.13)Sem cell transplantationYes0.07-0.07-0.020.74 (0.51-1.52)Yes0.07-0.07*-0.030.55 (0.36-0.85)**Yes<	Tumour type																																																																																																																																										
A·NHL-0.05-0.07-0.040.030.783 (0.48-1.28)HLRefRefRefRefMefMM-0.050.02-0.030.010.0100.010Age-0.050.01-0.12**-0.11**1.00 (0.99-1.01)Years sine diagnosis-0.010.010.02-0.050.97 (0.92-1.03)GenderWalkRefRefRefRefRefRefFemale0.010.02-0.01-0.010.77 (0.58-1.03)ChemotherapyNoRefRefRefRefRefYes0.03-0.010.14**0.14**1.81 (1.04-3.13)*RaidotherapyYes-0.06-0.06-0.071.00 (0.68-1.45)Arity surveillanceYes-0.06-0.06*-0.071.00 (0.68-1.45)Ster cell transplantationYes0.060.06*-0.071.00 (0.68-1.45)Yes0.070.060.16**NoneRefRefRefRefYes0.070.060.050.51 (0.73-3.13)ComorbidiYes0.07-0.020.74 (0.51-1.52)3 or more-0.07-0.020.74 (0.51-1.52)3 or more0.09* <td>I-NHL</td> <td>-0.07</td> <td>-0.07</td> <td>-0.12**</td> <td>-0.09</td> <td>0.89 (0.52–1.52)</td>	I-NHL	-0.07	-0.07	-0.12**	-0.09	0.89 (0.52–1.52)																																																																																																																																					
HLRefRefRefRefRefRefMM-0.050.02-0.030.000.81 (0.43-1.56)Age-0.050.01-0.12**-0.01 (0.09-1.01)Years since diagnosis0.010.01-0.12**1.00 (0.99-1.01)Gender-0.12**0.97 (0.92-1.03)GenderRefRefMaleRefRefRefRefRefFemale0.010.010.010.77 (0.58-1.03)ChemotherapyRefRefNoRefRefRefRefRefYes0.000.010.14*1.81 (1.0-3.13)*Radiotherapy1.01 (0.68-1.45)NoRefRefRefRefRefYes0.08-0.06-0.071.00 (0.68-1.45)Active surveillance-0.061.01 (0.68-1.45)NoRefRefRefRefYesNoRefRefRefRefYesNoRefRefRefStore	A-NHL	-0.05	-0.07	-0.04	0.03	0.783 (0.48–1.28)																																																																																																																																					
MM-0.050.02-0.030.010.12**-0.11**1.00 (0.99-1.01)Years since diagnosis-0.010.010.02-0.050.97 (0.92-1.03)Years since diagnosis-0.010.02-0.050.97 (0.92-1.03)GenderRefRefRefMaleRefRefRefRefRefFemale0.010.02-0.010.77 (0.58-1.03)Chemotherapy-0.010.77 (0.58-1.03)ChemotherapyRefRefRefYes0.03-0.010.14*0.14*1.81 (1.04-3.13)*Radiotherapy0.14*0.14*1.81 (1.04-3.13)*Radiotherapy0.16*0.071.00 (0.68-1.45)NoRefRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active survillance-0.061.39 (0.76-2.55)Stem cell transplantation-0.061.39 (0.76-2.55)Yes0.070.020.060.051.51 (0.73-3.13)Comorbidiy </td <td>HL</td> <td>Ref</td> <td>Ref</td> <td>Ref</td> <td>Ref</td> <td>Ref</td>	HL	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
Age-0.050.01-0.12**-0.11**1.00 (0.99-1.01)Years since diagnosis-0.010.02-0.050.97 (0.92-1.03)GenderRefRefRefMaleRefRefRefRefSetFemale0.010.02-0.01-0.010.77 (0.58-1.03)Chemotherapy-0.010.77 (0.58-1.03)NoRefRefRefRefRefYes0.03-0.010.14**0.14**1.81 (1.04-3.13)*Radiotherapy-0.010.14**1.81 (1.04-3.13)*Radiotherapy-0.010.14**1.81 (1.04-3.13)*Active surveillance-0.010.14**1.81 (1.04-3.13)*Yes0.03-0.06RefRefRefYesNoRefRefRefRefYesNeofe-1.45)Yes0.09-0.06-0.071.00 (0.66-1.45)NetYes0.09-0.06-0.061.50 (0.76-2.55)Stem cell transplantationNeofRefRefYes0.070.020.061.51 (0.73-3.13)Comorbidiy-0.010.55 (0.36-0.85)**Yes0.07-0.020.74 (0.51-1.52)2-0.07-0.02-0.010.55 (0.36-0.85)**3 or more-0.04-0.07-0.020.74 (0.51-1.52)Avital status-0.02-0.03 <td>MM</td> <td>-0.05</td> <td>0.02</td> <td>-0.03</td> <td>0.00</td> <td>0.81 (0.43–1.56)</td>	MM	-0.05	0.02	-0.03	0.00	0.81 (0.43–1.56)																																																																																																																																					
Years since diagnosis-0.010.010.02-0.050.97 (0.92-1.03)GenderMaleRefRefRefRefFemale0.010.02-0.010.07 (0.58-1.03)ChemotherapyNoRefRefRefRefYes0.00-0.010.14**01.81 (1.04-3.13)*RadiotherapyRadiotherapyWires-0.010.14**0Net (1.04-3.13)*RadiotherapyNoRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillanceView surveillanceYes-0.09-0.08-0.16**RefRefYes-0.09-0.06-0.061.39 (0.76-2.55)Stem cell transplantationNoRefRefRefRefRefYes-0.07-0.060.16*NoneRefRefRefRef-NoneRefRefRef1-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.90*-0.14**-0.010.55 (0.36-0.84)**Advintal stusPatterRefRefRefRef-No patter0.02-0.02-0.030.85 (0.52-1.38)Marial stus	Age	-0.05	0.01	-0.12**	-0.11**	1.00 (0.99–1.01)																																																																																																																																					
GenderMaleRefRefRefRefMaleRefRefRefRefFemale0.00.02.00.100.100.10ChemotherapyRefRefNoRefRefRefRefRefYes0.03-0.010.14*01.81 (1.04-3.13)*Radiotrapy </td <td>Years since diagnosis</td> <td>-0.01</td> <td>0.01</td> <td>0.02</td> <td>-0.05</td> <td>0.97 (0.92–1.03)</td>	Years since diagnosis	-0.01	0.01	0.02	-0.05	0.97 (0.92–1.03)																																																																																																																																					
MaleRefRefRefRefRefRefFemale0.010.02-0.01-0.010.77 (0.58-1.03)Chemokerapy-0.01-0.010.77 (0.58-1.03)NoRefRefRefRefRefRefYes0.03-0.010.14*00.14*11.81 (1.04-3.13)*Radiotherapy1.81 (1.04-3.13)*RadiotherapyNo1.81 (1.04-3.13)*Active surveillanceRefRefYes0.03-0.06.014*0NoNo (0.68-1.45)Active surveillanceRefRefYes-0.09-0.06.016*0.010*11.39 (0.76-2.55)Stem cell transplantationNo (0.68-1.45)Yes0.070.08.016*1.016*1.016*1.016*1Yes0.07.010*1.016*1.016*1.016*1.016*1OmorbidityRefRefRef1-0.070.01.016*1.016*1.016*1.016*12-0.09*1-0.07*1-0.01.055 (0.36-0.85)**.016*13 or more-0.90*1-0.01*1-0.01*1.055 (0.36-0.84)*.016*1Aritistatus.014**1.010*1.055 (0.36-0.85)**.016*1Harine KellRefRefRefRef.016*1.016*1.016*1 <t< td=""><td>Gender</td><td></td><td></td><td></td><td></td><td></td></t<>	Gender																																																																																																																																										
Female0.010.02-0.01-0.010.77 (0.58-1.03)ChemotherapyNoRefRefRefRefYes0.03-0.010.14*0.14*1.81 (1.04-3.13)*RadiotherapyNoRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillance-0.05-0.071.00 (0.68-1.45)Yes-0.08-0.06-0.06-0.071.00 (0.68-1.45)Yes-0.08RefRefRefRefYes-0.09-0.06-0.061.39 (0.76-2.55)Stem cell transplantation-0.050.061.39 (0.76-2.55)Yes0.07-0.080.050.061.51 (0.73-3.13)ComorbidityNo1.61 (0.73-3.13)NoneRefRefRefRef11-0.07-0.010.55 (0.36-0.85)**33 or more-0.07-0.020.74 (0.51-1.52)23 or more-0.09*-0.07*-0.010.55 (0.36-0.85)**Autial status-0.02-0.010.55 (0.36-0.85)**Indication level-0.02-0.030.55 (0.36-0.45)*Idention level-0.02-0.030.55 (0.36-0.45)*Idention level-0.02-0.030.55 (0.36-0.45)*Idention level-0.02-0.030.55 (0.36-0.45)*Idention level <td>Male</td> <td>Ref</td> <td>Ref</td> <td>Ref</td> <td>Ref</td> <td>Ref</td>	Male	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
ChemotherapyNoRefRefRefRefYes0.03-0.010.14*0.14*1.81 (1.04-3.13)*RadiotherapyNoRefRefRefRefYes-0.03-0.06-0.071.00 (0.68-1.45)Active surveillanceVerNoRefRefRefRefYes-0.02-0.16**No (0.68-1.45)Strive surveillanceNoRefRefRefRefYes-0.02Strine ransplantationRefRefRefRefYes0.070.020.050.061.51 (0.73-3.13)ComorbidityNoRefRefRefRef1.51 (0.51-1.52)2 or more-0.07-0.020.74 (0.51-1.52)-3 or more-0.03-0.05-0.04*-0.050.36-0.85)**Antrial statusParterRefRefRefRefRefNo parter0.02-0.020.030.55 (0.36-0.85)**No parter0.02-0.020.030.55 (0.36-0.85)**No parter0.02-0.020.030.55 (0.36-0.85)**Marial statusRefRefRefRefRefRefNo parter0.02 </td <td>Female</td> <td>0.01</td> <td>0.02</td> <td>-0.01</td> <td>-0.01</td> <td>0.77 (0.58–1.03)</td>	Female	0.01	0.02	-0.01	-0.01	0.77 (0.58–1.03)																																																																																																																																					
NoRefRefRefRefRefYes0.03-0.010.14*00.14**1.81 (1.04-3.13)*RadiotherapyNoRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillanceNoRefRefRefRefYes-0.09-0.08-0.16**-0.061.39 (0.76-2.55)Stem cell transplantationYes-0.090.080.01**-0.061.39 (0.75-2.55)Stem cell transplantationNoRefRefRefRefRefYes0.070.0600.050.061.51 (0.73-3.13)ComorbidityNoneRefRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.04-0.07*-0.010.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.85)**3 or more-0.90*-0.02*0.001.21 (0.84-1.73)HartnerRefRefRefRefSo partner0.02-0.020.030.85 (0.52-1.38)Modium-0.030.85 (0.52-1.38)MediumHighRefRef-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefSo partner-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRef <td>Chemotherapy</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Chemotherapy																																																																																																																																										
Yes0.03-0.010.14*0.14**1.81 (1.04-3.13)*RadiotherapyNoRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillanceNoRefRefRefRefYes-0.09-0.08-0.16**-0.061.39 (0.76-2.55)Stem cell transplantationNoRefRefRefRefYes0.070.060.050.061.51 (0.73-3.13)ComorbidityWith the seriesNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.04-0.07-0.010.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.85)**AntrareNefRefRefRefNopartner0.02-0.020.010.55 (0.36-0.85)**AntrareNo-0.02-0.030.55 (0.36-0.85)**AntrareNo-0.03-0.020.010.55 (0.52-1.38)Education level0.030.85 (0.52-1.38)Medium-0.03-0.04-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefHedium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighNo-0.08*-0.06RefRefNo-0.08*-0.06Re	No	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
RadiotherapyNoRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillanceNoRefRefRefRefYes-0.09-0.06**-0.06*RefYes-0.09RefRefRefStem cell transplantatomNoNoRefRefRefRefYes0.070.06*0.050.64*Yes0.070.060.051.51 (0.73-3.13)Comorbidity </td <td>Yes</td> <td>0.03</td> <td>-0.01</td> <td>0.14*</td> <td>0.14**</td> <td>1.81 (1.04–3.13)*</td>	Yes	0.03	-0.01	0.14*	0.14**	1.81 (1.04–3.13)*																																																																																																																																					
NoRefRefRefRefRefYes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillance-0.08-0.071.00 (0.68-1.45)NoRefRefRefRefRefYes-0.09-0.08-0.16**-0.091.39 (0.76-2.55)Stem cell transplantation-0.08-0.16**-0.091.39 (0.76-2.55)Stem cell transplantationRefRefRefRefYes0.070.080.050.061.51 (0.73-3.13)Comorbidity-0.07-0.020.74 (0.51-1.52)NoneRefRefRefRefRef1.41-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.09*-0.07*-0.010.55 (0.36-0.84)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital status-0.020.001.21 (0.84-1.73)Education level-0.020.001.21 (0.84-1.73)Education level-0.02-0.030.85 (0.52-1.38)Medium0.02-0.02-0.030.85 (0.52-1.38)MediumRefRefRefRefHighRefRefRefRefYesRefRefRefRefNo-0.03-0.050.81 (0.57-1.16)HighRefRefRef	Radiotherapy																																																																																																																																										
Yes-0.08-0.06-0.071.00 (0.68-1.45)Active surveillanceNoRefRefRefRefYes-0.09-0.08-0.16**-0.061.39 (0.76-2.55)Stern cell transplantationYes0.070.060.060.061.51 (0.73-3.13)OrmorbidityComorbidityNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLind-0.03-0.85 (0.52-1.38)-0.06-0.058.8 (0.52-1.38)Medium0.02-0.06-0.050.81 (0.57-1.16)-0.16HighRefRefRefRef-0.16-0.16HighRefRefRefRef-0.16-0.16YesRefRefRefRefRef-0.16-0.16YesRefRefRefRefRefRefRefYesRefRefRefRefRefRefRefYesRefRefRefRefRefRefRefRefNo-0.08*-0.08*-0.06-0.03 <t< td=""><td>No</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></t<>	No	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
Active surveillanceNoRefRefRefRefYes-0.09-0.08-0.16**-0.061.39 (0.76-2.55)Stem cell transplantationNoRefRefRefRefYes0.070.060.050.061.51 (0.73-3.13)ComorbidityNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.02-0.020.031.21 (0.84-1.73)Education levelLow0.02-0.04-0.030.85 (0.52-1.38)Medium-0.03-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefYesRefRefRefRefNo-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefYesRefRefRefRefNo-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefHighRefRefRefRefHighRefRefRefRefHighRefRefRefRefHighRefRefRefRef <t< td=""><td>Yes</td><td>-0.08</td><td>-0.06</td><td>-0.06</td><td>-0.07</td><td>1.00 (0.68–1.45)</td></t<>	Yes	-0.08	-0.06	-0.06	-0.07	1.00 (0.68–1.45)																																																																																																																																					
NoRefRefRefRefRefYes-0.09-0.08-0.16**-0.061.39 (0.76-2.55)Stem cell transplantationNoRefRefRefRefYes0.070.060.050.061.51 (0.73-3.13)ComorbidityVisoRefRefRefRefNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.02-0.020.031.21 (0.84-1.73)Education levelLow0.02-0.04-0.050.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.06-0.030.81 (0.57-1.16)No-0.08*-0.06-0.05-0.81 (0.57-1.16)HighRefRefRefRefNo-0.08*-0.06-0.030.81 (0.57-1.16)HighRefRefRefRefRefNo-0.08* <td>Active surveillance</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Active surveillance																																																																																																																																										
Yes-0.09-0.08-0.16**-0.061.39 (0.76-2.55)Stem cell transplantationNoRefRefRefRefYes0.070.060.050.061.51 (0.73-3.13)ComorbidityNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Aritrial status0.020.001.21 (0.84-1.73)PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.81 (0.57-1.16)HighRefRefRefRefRefYesRefRefRefRefRefNo-0.08*-0.06-0.050.81 (0.57-1.16)No-0.08*RefRefRefYesRefRefRefRefNo-0.08*RefRefRefNo-0.08*RefRefRefNo-0.08*RefRefRefNo-0.08*RefRefRefNo-0.08*RefRefRef <tr <="" td=""><td>No</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr> <tr><td>Stem cell transplantation         No         Ref         Ref         Ref         Ref           Yes         0.07         0.06         0.05         0.06         1.51 (0.73-3.13)           Comorbidity           0.07         0.06         1.51 (0.73-3.13)           Comorbidity                None         Ref         Ref         Ref         Ref           1         -0.07         -0.04         -0.07         -0.02         0.74 (0.51-1.52)           2         -0.07         -0.05         -0.14**         -0.03         0.55 (0.36-0.85)**           3 or more         -0.90*         -0.90*         -0.07*         -0.01         0.55 (0.36-0.84)**           Marital status          -0.90*         -0.07*         -0.01         0.55 (0.36-0.84)**           Mariter          0.10         0.02         -0.07*         -0.01         0.55 (0.36-0.84)**           Mariter           0.90*         -0.02         0.00         1.21 (0.84-1.73)           Education level            -0.02         -0.03         0.85 (0.52-1.38)           Medium         <td>Yes</td><td>-0.09</td><td>-0.08</td><td>-0.16**</td><td>-0.06</td><td>1.39 (0.76–2.55)</td></td></tr> <tr><td>NoRefRefRefRefRefYes0.070.060.050.061.51 (0.73–3.13)Comorbidity<!--</td--><td>Stem cell transplantation</td><td></td><td></td><td></td><td></td><td></td></td></tr> <tr><td>Yes0.070.060.050.061.51 (0.73–3.13)ComorbidityNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51–1.52)2-0.07-0.05-0.14**-0.030.55 (0.36–0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36–0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84–1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52–1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57–1.16)HighRefRefRefRefRefVes of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71–1.32)</td><td>No</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr> <tr><td>ComorbidityNoneRefRefRefRef1<math>-0.07</math><math>-0.04</math><math>-0.07</math><math>-0.02</math><math>0.74 (0.51-1.52)</math>2<math>-0.07</math><math>-0.05</math><math>-0.14**</math><math>-0.03</math><math>0.55 (0.36-0.85)**</math>3 or more<math>-0.90*</math><math>-0.07*</math><math>-0.01</math><math>0.55 (0.36-0.84)**</math>Marital status<math>-0.07*</math><math>-0.01</math><math>0.55 (0.36-0.84)**</math>PartnerRefRefRefRefNo partner<math>0.01</math><math>0.02</math><math>-0.02</math><math>0.00</math><math>1.21 (0.84-1.73)</math>Education level<math>-0.08*</math><math>-0.06</math><math>-0.05</math><math>0.85 (0.52-1.38)</math>Medium<math>-0.03</math><math>-0.08*</math><math>-0.06</math><math>-0.05</math><math>0.81 (0.57-1.16)</math>HighRefRefRefRefRefUse of internet<math>-0.07*</math><math>-0.04</math><math>-0.03</math><math>0.97 (0.71-1.32)</math></td><td>Yes</td><td>0.07</td><td>0.06</td><td>0.05</td><td>0.06</td><td>1.51 (0.73–3.13)</td></tr> <tr><td>NoneRefRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital status0.07*-0.010.55 (0.36-0.84)**PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education level0.030.85 (0.52-1.38)Medium-0.03-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)</td><td>Comorbidity</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)</td><td>None</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr> <tr><td>2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefVes of internet</td><td>1</td><td>-0.07</td><td>-0.04</td><td>-0.07</td><td>-0.02</td><td>0.74 (0.51–1.52)</td></tr> <tr><td>3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefVes of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)</td><td>2</td><td>-0.07</td><td>-0.05</td><td>-0.14**</td><td>-0.03</td><td>0.55 (0.36-0.85)**</td></tr> <tr><td>Marital status         Partner         Ref         Ref         Ref         Ref           No partner         0.01         0.02         -0.02         0.00         1.21 (0.84–1.73)           Education level          -0.02         -0.03         0.85 (0.52–1.38)           Medium         -0.03         -0.08*         -0.06         -0.05         0.81 (0.57–1.16)           High         Ref         Ref         Ref         Ref         Ref           Vse of internet         V         V         V         V         V           No         -0.08*         -0.04         -0.03         0.97 (0.71–1.32)</td><td>3 or more</td><td>-0.90*</td><td>-0.90*</td><td>-0.07*</td><td>-0.01</td><td>0.55 (0.36-0.84)**</td></tr> <tr><td>PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)</td><td>Marital status</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>No partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)</td><td>Partner</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr> <tr><td>Education level         Low       0.02       -0.04       -0.02       -0.03       0.85 (0.52-1.38)         Medium       -0.03       -0.08*       -0.06       -0.05       0.81 (0.57-1.16)         High       Ref       Ref       Ref       Ref       Ref         Vse of internet      </td><td>No partner</td><td>0.01</td><td>0.02</td><td>-0.02</td><td>0.00</td><td>1.21 (0.84–1.73)</td></tr> <tr><td>Low0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internet<!--</td--><td>Education level</td><td></td><td></td><td></td><td></td><td></td></td></tr> <tr><td>Medium         -0.03         -0.08*         -0.06         -0.05         0.81 (0.57-1.16)           High         Ref         Ref         Ref         Ref         Ref           Use of internet                Yes         Ref         Ref         Ref         Ref         Ref           No         -0.08*         -0.07*         -0.04         -0.03         0.97 (0.71-1.32)</td><td>Low</td><td>0.02</td><td>-0.04</td><td>-0.02</td><td>-0.03</td><td>0.85 (0.52–1.38)</td></tr> <tr><td>High         Ref         Ref         Ref         Ref           Use of internet        </td><td>Medium</td><td>-0.03</td><td>-0.08*</td><td>-0.06</td><td>-0.05</td><td>0.81 (0.57–1.16)</td></tr> <tr><td>Use of internet         Yes         Ref         Ref         Ref         Ref         Nef         Nef</td><td>High</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr> <tr><td>Yes         Ref         Ref         Ref         Ref           No         -0.08*         -0.07*         -0.04         -0.03         0.97 (0.71-1.32)</td><td>Use of internet</td><td></td><td></td><td></td><td></td><td></td></tr> <tr><td>No -0.08* -0.07* -0.04 -0.03 0.97 (0.71-1.32)</td><td>Yes</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr> <tr><td></td><td>No</td><td>-0.08*</td><td>-0.07*</td><td>-0.04</td><td>-0.03</td><td>0.97 (0.71–1.32)</td></tr>	No	Ref	Ref	Ref	Ref	Ref	Stem cell transplantation         No         Ref         Ref         Ref         Ref           Yes         0.07         0.06         0.05         0.06         1.51 (0.73-3.13)           Comorbidity           0.07         0.06         1.51 (0.73-3.13)           Comorbidity                None         Ref         Ref         Ref         Ref           1         -0.07         -0.04         -0.07         -0.02         0.74 (0.51-1.52)           2         -0.07         -0.05         -0.14**         -0.03         0.55 (0.36-0.85)**           3 or more         -0.90*         -0.90*         -0.07*         -0.01         0.55 (0.36-0.84)**           Marital status          -0.90*         -0.07*         -0.01         0.55 (0.36-0.84)**           Mariter          0.10         0.02         -0.07*         -0.01         0.55 (0.36-0.84)**           Mariter           0.90*         -0.02         0.00         1.21 (0.84-1.73)           Education level            -0.02         -0.03         0.85 (0.52-1.38)           Medium <td>Yes</td> <td>-0.09</td> <td>-0.08</td> <td>-0.16**</td> <td>-0.06</td> <td>1.39 (0.76–2.55)</td>	Yes	-0.09	-0.08	-0.16**	-0.06	1.39 (0.76–2.55)	NoRefRefRefRefRefYes0.070.060.050.061.51 (0.73–3.13)Comorbidity </td <td>Stem cell transplantation</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Stem cell transplantation						Yes0.070.060.050.061.51 (0.73–3.13)ComorbidityNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51–1.52)2-0.07-0.05-0.14**-0.030.55 (0.36–0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36–0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84–1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52–1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57–1.16)HighRefRefRefRefRefVes of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71–1.32)	No	Ref	Ref	Ref	Ref	Ref	ComorbidityNoneRefRefRefRef1 $-0.07$ $-0.04$ $-0.07$ $-0.02$ $0.74 (0.51-1.52)$ 2 $-0.07$ $-0.05$ $-0.14**$ $-0.03$ $0.55 (0.36-0.85)**$ 3 or more $-0.90*$ $-0.07*$ $-0.01$ $0.55 (0.36-0.84)**$ Marital status $-0.07*$ $-0.01$ $0.55 (0.36-0.84)**$ PartnerRefRefRefRefNo partner $0.01$ $0.02$ $-0.02$ $0.00$ $1.21 (0.84-1.73)$ Education level $-0.08*$ $-0.06$ $-0.05$ $0.85 (0.52-1.38)$ Medium $-0.03$ $-0.08*$ $-0.06$ $-0.05$ $0.81 (0.57-1.16)$ HighRefRefRefRefRefUse of internet $-0.07*$ $-0.04$ $-0.03$ $0.97 (0.71-1.32)$	Yes	0.07	0.06	0.05	0.06	1.51 (0.73–3.13)	NoneRefRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital status0.07*-0.010.55 (0.36-0.84)**PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education level0.030.85 (0.52-1.38)Medium-0.03-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	Comorbidity						1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	None	Ref	Ref	Ref	Ref	Ref	2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefVes of internet	1	-0.07	-0.04	-0.07	-0.02	0.74 (0.51–1.52)	3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefVes of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	2	-0.07	-0.05	-0.14**	-0.03	0.55 (0.36-0.85)**	Marital status         Partner         Ref         Ref         Ref         Ref           No partner         0.01         0.02         -0.02         0.00         1.21 (0.84–1.73)           Education level          -0.02         -0.03         0.85 (0.52–1.38)           Medium         -0.03         -0.08*         -0.06         -0.05         0.81 (0.57–1.16)           High         Ref         Ref         Ref         Ref         Ref           Vse of internet         V         V         V         V         V           No         -0.08*         -0.04         -0.03         0.97 (0.71–1.32)	3 or more	-0.90*	-0.90*	-0.07*	-0.01	0.55 (0.36-0.84)**	PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	Marital status						No partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	Partner	Ref	Ref	Ref	Ref	Ref	Education level         Low       0.02       -0.04       -0.02       -0.03       0.85 (0.52-1.38)         Medium       -0.03       -0.08*       -0.06       -0.05       0.81 (0.57-1.16)         High       Ref       Ref       Ref       Ref       Ref         Vse of internet	No partner	0.01	0.02	-0.02	0.00	1.21 (0.84–1.73)	Low0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internet </td <td>Education level</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Education level						Medium         -0.03         -0.08*         -0.06         -0.05         0.81 (0.57-1.16)           High         Ref         Ref         Ref         Ref         Ref           Use of internet                Yes         Ref         Ref         Ref         Ref         Ref           No         -0.08*         -0.07*         -0.04         -0.03         0.97 (0.71-1.32)	Low	0.02	-0.04	-0.02	-0.03	0.85 (0.52–1.38)	High         Ref         Ref         Ref         Ref           Use of internet	Medium	-0.03	-0.08*	-0.06	-0.05	0.81 (0.57–1.16)	Use of internet         Yes         Ref         Ref         Ref         Ref         Nef         Nef	High	Ref	Ref	Ref	Ref	Ref	Yes         Ref         Ref         Ref         Ref           No         -0.08*         -0.07*         -0.04         -0.03         0.97 (0.71-1.32)	Use of internet						No -0.08* -0.07* -0.04 -0.03 0.97 (0.71-1.32)	Yes	Ref	Ref	Ref	Ref	Ref		No	-0.08*	-0.07*	-0.04	-0.03	0.97 (0.71–1.32)
No	Ref	Ref	Ref	Ref	Ref																																																																																																																																						
Stem cell transplantation         No         Ref         Ref         Ref         Ref           Yes         0.07         0.06         0.05         0.06         1.51 (0.73-3.13)           Comorbidity           0.07         0.06         1.51 (0.73-3.13)           Comorbidity                None         Ref         Ref         Ref         Ref           1         -0.07         -0.04         -0.07         -0.02         0.74 (0.51-1.52)           2         -0.07         -0.05         -0.14**         -0.03         0.55 (0.36-0.85)**           3 or more         -0.90*         -0.90*         -0.07*         -0.01         0.55 (0.36-0.84)**           Marital status          -0.90*         -0.07*         -0.01         0.55 (0.36-0.84)**           Mariter          0.10         0.02         -0.07*         -0.01         0.55 (0.36-0.84)**           Mariter           0.90*         -0.02         0.00         1.21 (0.84-1.73)           Education level            -0.02         -0.03         0.85 (0.52-1.38)           Medium <td>Yes</td> <td>-0.09</td> <td>-0.08</td> <td>-0.16**</td> <td>-0.06</td> <td>1.39 (0.76–2.55)</td>	Yes	-0.09	-0.08	-0.16**	-0.06	1.39 (0.76–2.55)																																																																																																																																					
NoRefRefRefRefRefYes0.070.060.050.061.51 (0.73–3.13)Comorbidity </td <td>Stem cell transplantation</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Stem cell transplantation																																																																																																																																										
Yes0.070.060.050.061.51 (0.73–3.13)ComorbidityNoneRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51–1.52)2-0.07-0.05-0.14**-0.030.55 (0.36–0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36–0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84–1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52–1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57–1.16)HighRefRefRefRefRefVes of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71–1.32)	No	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
ComorbidityNoneRefRefRefRef1 $-0.07$ $-0.04$ $-0.07$ $-0.02$ $0.74 (0.51-1.52)$ 2 $-0.07$ $-0.05$ $-0.14**$ $-0.03$ $0.55 (0.36-0.85)**$ 3 or more $-0.90*$ $-0.07*$ $-0.01$ $0.55 (0.36-0.84)**$ Marital status $-0.07*$ $-0.01$ $0.55 (0.36-0.84)**$ PartnerRefRefRefRefNo partner $0.01$ $0.02$ $-0.02$ $0.00$ $1.21 (0.84-1.73)$ Education level $-0.08*$ $-0.06$ $-0.05$ $0.85 (0.52-1.38)$ Medium $-0.03$ $-0.08*$ $-0.06$ $-0.05$ $0.81 (0.57-1.16)$ HighRefRefRefRefRefUse of internet $-0.07*$ $-0.04$ $-0.03$ $0.97 (0.71-1.32)$	Yes	0.07	0.06	0.05	0.06	1.51 (0.73–3.13)																																																																																																																																					
NoneRefRefRefRefRef1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital status0.07*-0.010.55 (0.36-0.84)**PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education level0.030.85 (0.52-1.38)Medium-0.03-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	Comorbidity																																																																																																																																										
1-0.07-0.04-0.07-0.020.74 (0.51-1.52)2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	None	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
2-0.07-0.05-0.14**-0.030.55 (0.36-0.85)**3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefVes of internet	1	-0.07	-0.04	-0.07	-0.02	0.74 (0.51–1.52)																																																																																																																																					
3 or more-0.90*-0.07*-0.010.55 (0.36-0.84)**Marital statusPartnerRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefVes of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	2	-0.07	-0.05	-0.14**	-0.03	0.55 (0.36-0.85)**																																																																																																																																					
Marital status         Partner         Ref         Ref         Ref         Ref           No partner         0.01         0.02         -0.02         0.00         1.21 (0.84–1.73)           Education level          -0.02         -0.03         0.85 (0.52–1.38)           Medium         -0.03         -0.08*         -0.06         -0.05         0.81 (0.57–1.16)           High         Ref         Ref         Ref         Ref         Ref           Vse of internet         V         V         V         V         V           No         -0.08*         -0.04         -0.03         0.97 (0.71–1.32)	3 or more	-0.90*	-0.90*	-0.07*	-0.01	0.55 (0.36-0.84)**																																																																																																																																					
PartnerRefRefRefRefRefNo partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	Marital status																																																																																																																																										
No partner0.010.02-0.020.001.21 (0.84-1.73)Education levelLow0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internetYesRefRefRefRefRefNo-0.08*-0.07*-0.04-0.030.97 (0.71-1.32)	Partner	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
Education level         Low       0.02       -0.04       -0.02       -0.03       0.85 (0.52-1.38)         Medium       -0.03       -0.08*       -0.06       -0.05       0.81 (0.57-1.16)         High       Ref       Ref       Ref       Ref       Ref         Vse of internet	No partner	0.01	0.02	-0.02	0.00	1.21 (0.84–1.73)																																																																																																																																					
Low0.02-0.04-0.02-0.030.85 (0.52-1.38)Medium-0.03-0.08*-0.06-0.050.81 (0.57-1.16)HighRefRefRefRefRefUse of internet </td <td>Education level</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Education level																																																																																																																																										
Medium         -0.03         -0.08*         -0.06         -0.05         0.81 (0.57-1.16)           High         Ref         Ref         Ref         Ref         Ref           Use of internet                Yes         Ref         Ref         Ref         Ref         Ref           No         -0.08*         -0.07*         -0.04         -0.03         0.97 (0.71-1.32)	Low	0.02	-0.04	-0.02	-0.03	0.85 (0.52–1.38)																																																																																																																																					
High         Ref         Ref         Ref         Ref           Use of internet	Medium	-0.03	-0.08*	-0.06	-0.05	0.81 (0.57–1.16)																																																																																																																																					
Use of internet         Yes         Ref         Ref         Ref         Ref         Nef	High	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
Yes         Ref         Ref         Ref         Ref           No         -0.08*         -0.07*         -0.04         -0.03         0.97 (0.71-1.32)	Use of internet																																																																																																																																										
No -0.08* -0.07* -0.04 -0.03 0.97 (0.71-1.32)	Yes	Ref	Ref	Ref	Ref	Ref																																																																																																																																					
	No	-0.08*	-0.07*	-0.04	-0.03	0.97 (0.71–1.32)																																																																																																																																					

*I-NHL* indolent non-Hodgkin lymphoma, *A-NHL* aggressive non-Hodgkin lymphoma, *HL* Hodgkin lymphoma, *MM* multiple myeloma; Education levels included *low* no/primary school, *medium* lower general secondary education/vocational training, or *high* pre-university education/high vocational training/university

\**p*<.05; \*\**p*<.01

One third of survivors would have liked to receive more information. The topic that was mentioned most often was information on late effects (37-50 %) followed by information on the cause and course of the disease (24-59 %) and psychosocial aftercare (10-26 %). Inviting survivors for the

"BETTER" initiative could be an efficient solution to address these lasting information needs and leads to improved health care perception.

The present study has a few limitations. Although information was present concerning demographic and clinical characteristics of the non-respondents and patients with unverifiable addresses, it remains unknown why nonrespondents declined to participate in the study. In addition, the cross-sectional design of our study limits the determination of causal associations between the study variables. Furthermore, the mean time since diagnosis was 3.7 years, which could influence the recall effect of information received. However, in the case of indolent lymphoma and MM patients who visit their physicians more often, this may not have been a major problem as the majority of those patients (95 %) was still under active follow-up.

The strengths of our study are the population-based sampling frame instead of a hospital-based sampling frame, the high response rate and the large range in elapsed time since diagnosis. This facilitates to extrapolate the results to a broad range of lymphoma and MM survivors.

In conclusion, although information provision and satisfaction with information is relatively good in lymphoma and MM survivors, one third of the survivors were not satisfied with the perceived information provision, and variations between subgroups of patients were observed. The differences found between the participating hospitals with an assumed similar patient population suggest that there remains room for improvement. As survival of NHL, HL and MM has improved over the past decades and the numbers of long-term survivors increase, late effects of therapy become more important. Optimal, tailor-made and repeated information provision will lead to improved patient satisfaction and QoL. Implementation of survivorship care plans could contribute to the improvement of information provision [30].

Acknowledgments We thank all patients and their doctors for their participation in the study. Special thanks go to Dr. M. van Bommel for independent advice and answering questions of patients. The following hospitals provided cooperation: Catharina Hospital, Eindhoven; Jeroen Bosch Hospital, 's Hertogenbosch; Maxima Medical Centre, Eindhoven and Veldhoven; St. Anna Hospital, Geldrop; St. Elisabeth Hospital, Tilburg; Twee Steden Hospital, Tilburg; VieCuri Hospital, Venlo and Venray, Hospital Bernhoven, Oss. We thank the European Organization for Research and Treatment of Cancer for the use of the quality of life questionnaire.

**Funding** This study was financially supported by the Jonker-Driessen Foundation, ZonMW (the Netherlands organization for health research and development) for PHAROS: Population-based HAematological Registry for Observational Studies (#80-82500-98-01007.) and an Investment Subsidy (#480-08-009) of the Netherlands Organization for Scientific Research (The Hague, The Netherlands). Dr. Floortje Mols is supported by a VENI grant (#451-10-041) from the Netherlands Organization for Scientific Research (The Hague, The Netherlands), and Dr. Lonneke van de Poll-Franse is supported by a Cancer Research Award from the Dutch Cancer Society (#UVT-2009-4349).

Conflict of interest The authors state no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

## References

- Kankerbestrijding SvK. Kanker in Nederland tot 2020, Trends en prognoses. http://www.kankerbestrijding.nl 2011. Accessed 5 January 2012
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975\_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed 10 May 2011
- 3. Beter-projectgroep. Beter na Hodgkin. https://beternahodgkin.nl. Accessed 10 January 2012
- McInnes DK, Cleary PD, Stein KD et al (2008) Perceptions of cancer-related information among cancer survivors: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer 113:1471–1479
- Davies NJ, Kinman G, Thomas RJ, Bailey T (2008) Information satisfaction in breast and prostate cancer patients: implications for quality of life. Psychooncology 17:1048–1052
- Degner LF, Davison BJ, Sloan JA, Mueller B (1998) Development of a scale to measure information needs in cancer care. J Nurs Meas 6:137–153
- Butow PN, Kazemi JN, Beeney LJ et al (1996) When the diagnosis is cancer: patient communication experiences and preferences. Cancer 77:2630–2637
- Husson O, Mols F, van de Poll-Franse LV (2011) The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol 22:761–772
- 9. Kvam AK, Fayers P, Hjermstad M et al (2009) Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83:279–289
- Oerlemans S, Mols F, Nijziel MR et al (2011) The impact of treatment, socio-demographic and clinical characteristics on healthrelated quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol 90:993–1004
- 11. Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva
- 12. van de Poll-Franse LV, Horevoorts N, Eenbergen MV et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–94
- Arraras JI, Kuljanic-Vlasic K, Bjordal K et al (2007) EORTC QLQ-INFO26: a questionnaire to assess information given to cancer patients a preliminary analysis in eight countries. Psychooncology 16:249–254
- Arraras JI, Greimel E, Sezer O et al (2010) An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer 46:2726–2738
- Sangha O, Stucki G, Liang MH et al (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49:156– 163

- Carbone PP, Kaplan HS, Musshoff K et al (1971) Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860–1861
- Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
- (EORTC) EOfRaToC. http://groups.cortc.be/qol/documentation\_ manuals. Accessed 6 September 2011
- Beckjord EB, Arora NK, McLaughlin W et al (2008) Health-related information needs in a large and diverse sample of adult cancer survivors: implications for cancer care. J Cancer Surviv 2:179–189
- Davis TC, Dolan NC, Ferreira MR et al (2001) The role of inadequate health literacy skills in colorectal cancer screening. Cancer Invest 19:193–200
- 21. Davis TC, Williams MV, Marin E et al (2002) Health literacy and cancer communication. CA Cancer J Clin 52:134–149
- 22. Husson O, Holterhues C, Mols F et al (2010) Melanoma survivors are dissatisfied with perceived information about their diagnosis, treatment and follow-up care. Br J Dermatol 163:879–881
- Jones R, Pearson J, McGregor S et al (1999) Cross sectional survey of patients' satisfaction with information about cancer. BMJ 319:1247–1248

- 24. Rutten LJ, Arora NK, Bakos AD et al (2005) Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Educ Couns 57:250–261
- 25. Jansen J, van Weert J, van Dulmen S et al (2007) Patient education about treatment in cancer care: an overview of the literature on older patients' needs. Cancer Nurs 30:251–260
- Petersson LM, Nordin K, Glimelius B et al (2002) Differential effects of cancer rehabilitation depending on diagnosis and patients' cognitive coping style. Psychosom Med 64:971–980
- 27. Crow R, Gage H, Hampson S et al (2002) The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature. Health Technol Assess 6:1–244
- Matsuyama RK, Wilson-Genderson M, Kuhn L et al (2011) Education level, not health literacy, associated with information needs for patients with cancer. Patient Educ Couns 85(3):e229–36
- Nielsen-Bohlman L, Panzer A, Kindig D (2004) Health literacy: a prescription to end confusion. National Academies Press, Washington, DC
- Hewitt M, Greenfield S, Stovall E (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington, DC